Federal Register / Vol. 62, No. 227 / Tuesday, November 25, 1997 / Notices 62781

Time: 11:00 a.m.

Place: NIH, Rockledge 2, Room 5198,

Telephone Conference.

Contact Person: Dr. Michael Micklin,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5198, Bethesda,

Maryland 20892, (301) 435–1258.

Name of SEP: Biological and Physiological

Sciences.

Date: December 8, 1997.

Time: 10:00 a.m.

Place: NIH, Rockledge 2, Room 5202,

Telephone Conference.

Contact Person: Dr. Anita Sostek, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 5202, Bethesda, Maryland 20892, (301)

435–1260.

Name of SEP: Biological and Physiological

Sciences.

Date: December 10, 1997.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4208,

Telephone Conference.

Contact Person: Dr. Anita Weinblatt,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4208, Bethesda,

Maryland 20892, (301) 435–1224.

Name of SEP: Clinical Sciences.

Date: December 10, 1997.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4112,

Telephone Conference.

Contact Person: Dr. Gopal Sharma,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4112, Bethesda,

Maryland 20892, (301) 435–1783.

Name of SEP: Clinical Sciences.

Date: December 11, 1997.

Time: 11:00 a.m.

Place: NIH, Rockledge 2, Room 4138,

Telephone Conference.

Contact Person: Dr. Anthony Chung,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4138, Bethesda,

Maryland 20892, (301) 435–1213.

Name of SEP: Biological and Physiological

Sciences.

Date: December 11, 1997.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4202,

Telephone Conference.

Contact Person: Dr. Gene Zimmerman,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4202, Bethesda,

Maryland 20892, (301) 435–1220.

Name of SEP: Biological and Physiological

Sciences.

Date: December 11, 1997.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4208,

Telephone Conference.

Contact Person: Dr. Anita Weinblatt,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4208, Bethesda,

Maryland 20892, (301) 435–1224.

Name of SEP: Chemistry and Related

Sciences.

Date: December 11, 1997.

Time: 12:00 p.m.

Place: NIH, Rockledge 2, Room 4172,

Telephone Conference.

Contact Person: Dr. Donald Schneider,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4172, Bethesda,

Maryland 20892, (301) 435–1727.

Name of SEP: Biological and Physiological

Sciences.

Date: December 18, 1997.

Time: 9:00 a.m.

Place: NIH, Rockledge 2, Room 5196,

Telephone Conference.

Contact Person: Ms. Carol Campbell,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5196, Bethesda,

Maryland 20892, (301) 435–1257.

Purpose/Agenda: To review Small

Business Innovation Research.

Name of SEP: Microbiological and

Immunological Sciences.

Date: November 21, 1997.

Time: 1:00 p.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Gilbert Meir, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 5112, Bethesda, Maryland 20892, (301)

455–1169.

The notice is being published less than 15

days prior to the above meeting due to the

urgent need to meet timing limitations

imposed by the grant review and funding

cycle.

Name of SEP: Behavioral and

Neurosciences.

Date: December 2, 1997.

Time: 8:30 a.m.

Place: Holiday Inn, Silver Spring, MD.

Contact Person: Dr. Leonard Jakubczak,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5172, Bethesda,

Maryland 20892, (301) 435–1247.

Name of SEP: Microbiological and

Immunological Sciences.

Date: December 2, 1997.

Time: 8:30 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Gilbert Meier,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5112, Bethesda,

Maryland 20892, (301) 435–1219.

Name of SEP: Microbiological and

Immunological Sciences.

Date: December 3, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 5112,

Telephone Conference.

Contact Person: Dr. Gilbert Meier,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5112, Bethesda,

Maryland 20892, (301) 435–1219.

The meetings will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(b), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93,893, National Institutes of Health,

HHS)

Dated: November 18, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–30930 Filed 11–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Pigment Epithelium Derived

Growth Factor

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I), announces that the

National Institutes of Health is

contemplating the grant of an exclusive

world-wide license to GenVec, Inc., a

Delaware corporation headquartered in

Rockville, Maryland to practice the

inventions embodied in the U.S. Patent

Applications listed below (and

corresponding foreign patent

applications) in the field of ocular gene

therapy. These inventions are owned by

the Government of the United States of

America as represented by the

Department of Health and Human

Services.

1. USSN 07/952,796 entitled ‘‘DNA

Clones for the Expression of Pigment

Epithelium Derived Growth Factor and

Related Proteins’’ filed September 24,

1992 by Fintan R. Steele, Gerald J.

Chader, Joyce Tombran-Tink and Sofia

P. Becerra.

2. USSN 08/257,963 entitled

‘‘Pigment Epithelium Derived Factor:

Characterizations of Its Biological

Activity and Sequences Encoding and

Expressing the Protein’’ filed June 7,

1994 by Gerald J. Chader, Sofia P.

Becerra, Joan P. Schwartz, Takayuki

Taniwaki and Yukihera Sugita.

3. USSN 08/279,979 entitled ‘‘Retinal

Pigmented Epithelium Derived

Neurotrophic Factor’’ filed July 25, 1994

by Fintan R. Steele, Gerald J. Chader,

Joyce Tombran-Tink, Sofia P. Becerra

and Ignacio R. Rodriquez and Lincoln

Johnson.

4. USSN 08/367,841 entitled

‘‘Pigment Epithelium Derived Factor:

Characterization, Genomic Organization

and Sequence of the PEDF Gene’’ filed

December 30, 1994 by Gerald J. Chader,

Joyce Tombran-Tink, Sofia P. Becerra,

Ignacio R. Rodriquez and Fintan R.

Steele and Lincoln Johnson.

5. USSN 08/377,710 entitled ‘‘DNA

Clones for the Expression of Pigment

Epithelium Derived Factor and Related

Proteins’’ filed January 25, 1995 by

Fintan R. Steele, Gerald L. Chader, Joyce

Tombran-Tink, Sofia P. Becerra and

Ignacio R. Rodriquez.

6. USSN 08/520,373 entitled ‘‘Retinal

Pigmented Epithelium Derived
62782 Federal Register / Vol. 62, No. 227 / Tuesday, November 25, 1997 / Notices

Neurotrophic Factor’’ filed August 29,

1995 by Gerald J. Chader, Joyce

Tombran-Tink, Sofia P. Becerra, Ignacio

R. Rodriquez and Fintan R. Steele.

DATES: Only written comments and/or

applications for a license which are

received by NIH on or before January 26,

1998 will be considered.

ADDRESSES: Requests for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated licenses should be

directed to: Jaconda Wagner, Esq.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: (301)

496–7735 ext. 284; Facsimile: (301)

402–0220. A signed Confidentiality

Agreement will be required to receive

copies of the patent applications.

SUPPLEMENTARY INFORMATION: Cultured

retinal pigment epithelium (RPE) cells

secrete pigment epithelium-derived

factor (PEDF) into the photoreceptor

matrix. This protein, with a molecular

weight of approximately 50 kD, has

trophic activity which induces neuronal

cell differentiation, survival of mature

neurons and a gliastatic effect. This

technology can be used to develop

therapeutics for the treatment of

inflammatory, vascular, degenerative

and dystrophic diseases of the retina

and central nervous system (CNS) as

well as to treat cancers of the CNS and

conditions resulting from the activity of

serine proteases.

The various patent applications

encompassing this invention contain

claims to a recombinant DNA molecule

comprising a gene encoding the PEDF;

an organism transformed with the

recombinant DNA molecule; a method

of treating tumors ocular diseases, nerve

injuries and conditions resulting from

the activity of serine proteases using the

PEDF; the PEDF protein and its

biological activity, specifically a method

of enhancing neuron cell survival and

inhibiting glial cell proliferation;

purified antibodies to PEDF; a method

for purifying the PEDF; and

immunoassay for detecting the level of

PEDF in a sample.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

Applications for a license in the field

of use filed in response to this notice

will be treated as objections to the grant

of the contemplated licenses. Comments

and objections submitted to this notice

will not be made available for public

inspection and, to the extent permitted

by law, will not be released under the

Freedom of Information Act, 5 U.S.C.

552.

Dated: November 14, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–30924 Filed 11–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4263–N–58]

Notice of Proposed Information

Collection for Public Comment

AGENCY: Office of the Assistant

Secretary for Policy Development and

Research, HUD.

ACTION: Notice.

SUMMARY: The proposed collection

requirement described below will be

submitted to the Office of Management

and Budget (OMB) for review, as

required by the Paperwork Reduction

Act. The Department is soliciting public

comments on the subject proposal.

DATES: Comments due: January 26,

1998.

ADDRESSES: Interested persons are

invited to submit comments regarding

this proposal. Comments should refer to

the proposal by name and/or OMB

Control Number and should be sent to:

Reports Liaison Officer, Policy

Development & Research, Department of

Housing & Urban Development, 451—

7th Street, SW, Room 8228, Washington,

DC 20410.

FOR FURTHER INFORMATION CONTACT:

Alan Rothman, Social Science Research

Analyst, Office of Policy Development

and Research—telephone (202) 708–

4370, x139 (this is not a toll-free

number) for copies of the proposed

forms and other available documents.

SUPPLEMENTARY INFORMATION: The

Department will submit the proposed

information collection to OMB for

review, as required by the Paperwork

Reduction Act of 1995 (44 U.S.C.

Chapter 35, as amended).

The office is soliciting comments from

members of the public and affected

agencies concerning the proposed

collection of information to: (1) Evaluate

whether the proposed collection of

information is necessary for the proper

performance of the functions of the

agency, including whether the

information will have practical utility;

(2) Evaluate the accuracy of the agency’s

estimate of the burden of the proposed

collection of information; (3) Enhance

the quality, utility, and clarity of the

information to be collected; and (4)

Minimize the burden of the collection of

information on those who are to

respond; including through the use of

appropriate automated collection

techniques or other forms of information

technology, e.g., permitting electronic

submission of responses.

This notice also lists the following

information:

Title of Proposal: Assessment and

Analysis of Multifamily Building’s

Conformity with Fair Housing

Guidelines Provisions

OMB Control Number: None.

Description of the Need for

Information and the Proposed Use: The

Fair Housing Amendment Act (the Act)

of 1988 requires that newly constructed

multifamily dwellings covered under

the Act, available for first occupancy

after March 13, 1991, be designated and

constructed to be accessible to persons

with disabilities. The purpose of this

project is to assess the extent of

conformity with the accessibility

provisions and examine reasons for, as

well as explanations, for different

patterns of conformity/non-conformity.

Agency Form Numbers: Not

applicable.

Members of the Affected Public:

Property owners, property management

personnel, occupants, local code

officials, architects, engineers, and

builders.

Estimation of the Total Number of

Hours Needed to Prepare the

Information Collection Including

Number of Respondents, Frequency of

Response, and Hours of Response:

Grand total hours for all personnel is

11,936 labor hours over ninety (90)

weeks. Total hours for contractor

personnel is estimated at 10,900 hours.

The total hours for voluntary one-time

responses, from management/owners/

project representatives and residents, is

1,036 hours for the 386 projects to be

considered in the statistical model. The

hour breakdown for the survey

respondents is 128 hours during the

mobilization phase, 803 hours during

Phase I—survey/data gathering efforts,

and 105 hours for Phase II—assessment

and analysis effort.

Status of the Proposed Information

Collection: Pending OMB approval.

Authority: Section 3506 of the Paperwork

Reduction Act of 1995, 44 U.S.C. Chapter 35,

as amended.